Results 31 to 40 of about 9,749 (194)
Indian Journal of Transplantation, 2022 Background: With the rising incidence of diabetes and hypertension, the prevalence of end-stage renal disease has increased greatly so as the need for renal replacement therapy.
Kandasamy Sadayandi +10 more
doaj +1 more source
, 2003 Objective: To compare resource use and costs in renal transplant recipients treated with basiliximab or placebo plus triple immunosuppressive therapy.
Whitfield, Malcolm +3 more
core +6 more sources
OncoImmunology, 2017 Acute graft versus host disease (aGVHD) remains a major problem after allogeneic hematopoietic stem cell transplantation. Standard frontline therapy for aGVHD involves corticosteroids. However, fewer than half of patients have a lasting complete response.
Yamin Tan +21 more
doaj +1 more source
Thymoglobuline plus basiliximab a mixed cocktail to start?
, 2017 Recent results reported by Ciancio et al. have demonstrated the long term successful use of dual induction therapy in kidney transplant recipients. Our experience using an “induction cocktail”, thymoglobuline plus basiliximab, started in 2007 and we have
Franco Citterio +9 more
core +1 more source
Revista Clínica de la Escuela de Medicina UCR-HSJD, 2011 Antecedentes El rechazo agudo del injerto es unacomplicación importante en pacientes sometidosa trasplante renal. El presente estudio buscacomparar el porcentaje de rechazo agudo delinjerto en el primer año del trasplante renal alhaber recibido ...
Jorge Andrés Umaña González +2 more
doaj +1 more source
Induction Immunosuppression with Basiliximab in Heart Transplantation
, 2011 After clinical heart transplantation (HT), it is crucial to use appropriate immunosuppressive agents to prevent rejection. The use of basiliximab or rabbit anti-thymocyte globulin (RATG) for induction therapy has significantly reduced the incidence of ...
CHOU, NAI-KUAN;WANG, SHOEI-SHEN;CHEN, YIH-SHARNG;YU, HSI-YU;CHI, NAI-HSIN;WANG, CHIH-HSIEN;KO, WEN-JE;TSAO, CHUAN-I;SHUN, CHIA-TUNG +1 more
core +1 more source
, 2022 BackgroundInduction therapy is used in about 80% of lung transplant centers and is increasing globally. Currently, there are no standards or guidelines for the use of induction therapy.
Jenalee N. Coster (12707318) +10 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani +4 more
wiley +1 more source
Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation [PDF]
Clinical and Molecular Hepatology, 2014 Background/AimsThe most commonly used immunosuppressant therapy after liver transplantation (LT) is a combination of tacrolimus and steroid. Basiliximab induction has recently been introduced; however, the most appropriate immunosuppression for ...
Ju-Yeun Lee +10 more
doaj +1 more source
, 2021 Background: Induction therapy with biological agents as anti-thymocyte globulin (ATG) or an interleukin 2 receptor antagonist (IL2-RA) is essential to reduce the risk of acute rejection.Though ATG is used selectively in patients with high immunological ...
Alrofie, Fatima Mugdad Ahmed +1 more
core +1 more source